MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
As usual medtech titan Medtronic (NYSE:MDT) kept up its lead with a raft of stories about legal battles, recalls and progress toward an artificial pancreas. St. Jude Medical (NYSE:STJ) jumped up to 2nd place with updates about several of its technologies, including the troubled Riata leads, the newer Durata leads, CRM systems and more.
Covidien (NYSE:COV) maintained its 3rd-place seat with just a handful of stories as the company put the final touches on its transition to a pure-play medtech company. Boston Scientific (NYSE:BSX) also maintained its spot, with R&D updates, legal news and the acquisition of C.R. Bard’s (NYSE:BCR) electrophysiology business.
Aesthetics devices maker Allergan (NYSE:AGN) returned to the list, with some personnel shuffling and insight from CEO David Pyott.
Medtronic
- Judge boosts royalties for NuVasive in patent loss to Medtronic
- Medtronic notches small win in German TAVI war with Edwards Lifesciences
- Spinal: Medtronic touts Euro win for 1st-of-its kind ReDux Plier
- Real-world results cast doubt on renal denervation for high blood pressure
- Yale study of Medtronic’s Infuse shows it’s equivalent to bone graft, but studies were biased
- Medtronic ticks up on share buyback, dividend
- Recalls: Medtronic pulls Trivantage tracheal tube, Paradigm and Polyfin insulin pumps
- Diabetes: Medtronic makes progress toward artificial pancreas, touts NEJM study
- Minnesota feds probe Medtronic over Trade Agreements Act
- FDA blocks Medtronic catheters, cites manufacturing violations at Italian facility
- More warnings for Medtronic’s SynchroMed implantable drug pumps
- Medtronic legal counsel heads to greener pastures
- Medtronic’s latest pain pump warnings get FDA’s Class I status
- St. Jude Medical launches MRI-safe pacemaker system in Japan
- Podcast: Medtronic CEO Omar Ishrak on emerging markets, economic value and the medtech tax
- Federal Circuit again invalidates Cordis patent claims against Medtronic, Abbott, Boston Sci.
- Diabetes: The Path To An Artificial Pancreas Looks A Little More Reasonable
St. Jude Medical
- St. Jude is "feeling really good" about Durata
- St. Jude gets the green light for U.S. EnligHTN IV renal denervation study
- Pain management: St. Jude pays $40M for exclusive purchase option for Spinal Modulation
- FDA approves new safety features in St. Jude’s next-gen high-voltage defibrillators
- St. Jude’s Durata defibrillator ‘immune’ to Riata flaws?
- St. Jude lands E.U. win for next-gen multi-point defibrillator
- St. Jude’s Amplatzer looks better in new analysis
- St. Jude Medical launches MRI-safe pacemaker system in Japan
Covidien
- Covidien CEO Almeida wants more from emerging markets
- Aneurysm: Covidien touts pivotal study on Pipeline embolization device
- Covidien’s Mallinckrodt pharma spinout slated to close this month
Boston Scientific
- Boston Scientific can’t escape New Jersey whistleblower lawsuit
- Boston Scientific warns of labeling issues in balloon dilators, catheters
- Boston Scientific launches U.S. Parkinson’s trial, cites interim EU data
- Europace: Boston Scientific touts new safety results for its lead-free S-ICD
- C.R. Bard deals electrophysiology biz to Boston Scientific
- Federal Circuit again invalidates Cordis patent claims against Medtronic, Abbott, Boston Sci.
Allergan
- Podcast: Allergan CEO David Pyott at the MassDevice Big 100 West
- CEO Insight: Allergan’s David Pyott Medicare and the medical device tax
- CEO Insight: Allergan’s David Pyott on the federal Sunshine Act
- Allergan promotes a company VP to president
